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Abstract 
Background: Gestational diabetes mellitus (GDM) increases the risk for preeclampsia and macrosomia. GDM is con-
ventionally diagnosed by an oral glucose tolerance test (OGTT). Hemoglobin A1c (HbA1c) is a marker for the average 
glucose level the last 2–3 months. We aimed to study if HbA1c alone or in combination with patient characteristics 
can be used to screen for GDM and reduce the number of OGTTs, and whether it could predict preeclampsia or birth 
weight.
Methods: 855 women from a previous study on the effect of exercise on GDM prevalence were eligible, whereof 677 
were included. GDM was diagnosed by WHO 1999 criteria (GDM-WHO) and modified IADPSG criteria (GDM-IADPSG), 
at pregnancy weeks 18–22 and 32–36. HbA1c analyzed at pregnancy weeks 18–22 and 32–36, variables from patient 
history and clinical examination were considered for logistic regression models. The diagnostic accuracy was assessed 
by ROC curve analysis.
Results: Accumulated GDM prevalence was 6.7 % by WHO and 7.2 % by modified IADPSG criteria. Nearly a third 
could potentially have avoided an OGTT by using HbA1c to exclude GDM-IADPSG with a sensitivity of 88 % at week 
18–22 and 97 % at week 32–36. Further, 16 % could have avoided an OGTT with a sensitivity of 96 % using HbA1c at 
week 18–22 to exclude GDM-IADPSG throughout pregnancy. HbA1c was not accurate at diagnosing GDM-IADPSG, 
and it was inaccurate at screening for GDM-WHO at any time point. Adding other predictors did not increase the 
number of potentially avoidable OGTTs significantly. HbA1c was not significantly associated with preeclampsia or 
birth weight.
Conclusions: HbA1c could potentially reduce the number of OGTTs.
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Background
Women with gestational diabetes mellitus (GDM) 
have an increased risk of obstetrical complications and 
adverse pregnancy outcomes such as preeclampsia and 
macrosomia [1]. According to a review, GDM preva-
lences of 2–6 % were most often reported in Europe [2]. 
GDM is usually diagnosed by an oral glucose tolerance 
test (OGTT) [2]. However, the OGTT is time-consuming 
for both the women and the health care system as the 
women need to be fasting and wait for 2 h to complete 
the test [2], and an OGTT may induce or aggravate nau-
sea and vomiting in pregnant women, i.e. some fail to 
complete the test.
There is no international consensus on screening for 
GDM. Some European countries recommend screen-
ing all pregnant women with OGTT, whereas others use 
selective screening based on risk factors or a glucose 
challenge test [2]. In 2010 new criteria and universal 
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Association of Diabetes and Pregnancy Study Groups 
(IADPSG), i.e. the IADPSG criteria [3]. So far only a few 
studies on screening tests for the IADPSG criteria are 
published [4].
Over the last years, hemoglobin A1c (HbA1c), a marker 
representing the average of plasma glucose level in the 
last 8–12  weeks [5], has been endorsed as a diagnostic 
marker for diabetes mellitus in non-pregnant subjects 
[6]. HbA1c has advantages compared to the OGTT as 
the blood sample can be drawn in a non-fasting state 
and there is no need for glucose ingestion or timed blood 
sampling [6]. Further, the sample stability is better for 
HbA1c than for plasma glucose [6]. Studies examin-
ing HbA1c as a screening test for GDM have been pub-
lished [7–13]. They are difficult to compare, especially 
due to different diagnostic criteria for GDM, and no 
obvious diagnostic threshold has been identified [4]. 
More research is needed on HbA1c as a screening tool 
for GDM [14]. We aimed to investigate if HbA1c at preg-
nancy weeks 18–22, or 32–36 or HbA1c in combination 
with other clinical data could be used to screen for GDM 
and potentially reduce the number of OGTTs. Further, 
we wanted to examine if HbA1c could predict preec-
lampsia and birth weight.
Methods
Study population
We used data from a previously reported randomized 
controlled trial comparing the effect of a 12-week regu-
lar exercise program to standard antenatal care on GDM 
prevalence [15]. Pregnant women booking an appoint-
ment for ultrasound scan in gestational week 18 at St. 
Olavs Hospital (Trondheim University Hospital) from 
April 2007 to June 2009 and Stavanger University Hos-
pital from October 2007 to January 2009 were invited 
to participate. More than 97  % of pregnant Norwegian 
women attend a free of charge ultrasound scan around 
week 18. During the study period around 12,000 women 
had routine ultrasound scans at the two study centers 
and were eligible for the study. Inclusion criteria were 
age ≥18 years and a singleton viable fetus. Exclusion cri-
teria were high-risk pregnancies or diseases that could 
interfere with participation. In addition, women who 
lived more than 30 min drive from the study center were 
excluded due to practical reasons. A total of 875 women 
consented to participate, whereof 20 were excluded due 
to twin pregnancies (n = 2), miscarriages (n = 5) and not 
meeting inclusion criteria (n = 13). Data was collected at 
inclusion (week 18–22) and follow-up (week 32–36). All 
participants gave written informed consent. The study 
was approved by the Committee for Medical Research 
Ethics of Health Region IV in Norway (REK 4.2007.81) 
and is registered at http://www.clinicaltrials.gov as NCT 
00476567. The Declaration of Helsinki was followed 
throughout the study.
Women in the intervention group received a stand-
ardized exercise program of 60  min duration includ-
ing aerobic activity, strength training and balance 
exercises instructed by a physiotherapist once a week 
over a 12-week period. They were encouraged to fol-
low a 45 min home exercise program (30 min endurance 
training and 15  min strength and balance exercises) at 
least twice a week. Women in the control group received 
standard antenatal care and the customary information 
given by their midwife or general practitioner. They were 
not discouraged from exercising on their own. Women 
in both groups received written recommendations on 
diet, pelvic floor muscle exercises, and pregnancy-related 
lumbo-pelvic pain.
Women diagnosed with GDM by the World Health 
Organization (WHO) criteria from 1999 [16] during 
the study period received standard treatment for GDM, 
i.e. initially diet and life style advice. Insulin treatment 
was considered if serum glucose (s-glucose) was per-
sistently elevated, i.e. fasting s-glucose >6.0  mmol/L or 
>8.0  mmol/L 1–1.5  h after a meal. None of the partici-
pants needed insulin treatment.
Clinical data
Age, smoking status and information regarding previ-
ous pregnancies and family history of diabetes were col-
lected through questionnaires. Macrosomia was defined 
as birth weight >4000 g. Weight, height and blood pres-
sure were measured at pregnancy weeks 18–22. After 
15  min rest, blood pressure was measured three times 
with 2 min break between measurements. The average of 
the two last measurements was used. Data on pregnancy 
complications and adverse outcomes were obtained from 
medical records. Preeclampsia was defined as systolic 
blood pressure over 140  mmHg and/or diastolic blood 
pressure over 90  mmHg and proteinuria ≥0.3  g/24  h 
measured more than once 4–6  h apart occurring after 
gestational week 20.
Diagnostic criteria
GDM was diagnosed at pregnancy weeks 18–22 and 
32–36 by the WHO criteria from 1999 as fasting s-glu-
cose ≥7.0  mmol/L or s-glucose ≥7.8  mmol/L 2  h after 
ingesting 75  g glucose orally (OGTT) [16]. After the 
study we also diagnosed GDM according to modified 
IADPSG criteria as fasting s-glucose ≥5.1  mmol/L or 
s-glucose ≥8.5 mmol/L 2 h after the glucose load [3]. We 
could only use modified IADPSG criteria since we did not 
have 1-h s-glucose. GDM diagnosed by the WHO crite-
ria will hereafter be named GDM-WHO and by modified 
IADPSG criteria will be named GDM-IADPSG.
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Laboratory analyses
Fasting and 2-h glucose levels were measured in serum 
by the routine methods used by the hospital laboratory.
Venous blood samples from pregnancy weeks 18–22 
and 32–36 were stored at −80  °C. HbA1c is stable at 
these storage conditions [17, 18]. HbA1c was analyzed 
over a 3-week period in October 2014 at our hospital 
laboratory with an immunological method on a Roche 
Cobas Integra (Roche Diagnostics, Mannheim, Germany) 
[19]. The method was calibrated against the standard 
from the International Federation of Clinical Chemistry 
and Laboratory Medicine [20]. The coefficient of varia-
tion for within-laboratory imprecision during the 3-week 
period was 2.0  % at HbA1c 5.2  % (33  mmol/mol) and 
1.4 % at HbA1c 9.6 % (81 mmol/mol) [21].
Statistical analyses
To evaluate if HbA1c could potentially reduce the number 
of OGTTs we used a diagnostic threshold with high sen-
sitivity to rule-out GDM and a threshold with high speci-
ficity to rule-in GDM. Those between the two thresholds 
would need an OGTT to clarify whether they had GDM 
or not. We evaluated if HbA1c at weeks 18–22 could pre-
dict GDM at 18–22  weeks of pregnancy, and if it could 
predict GDM throughout pregnancy, i.e. GDM diagnosed 
at weeks 18–22 and 32–36 combined. We also evaluated if 
HbA1c at pregnancy weeks 32–36 could predict GDM at 
weeks 32–36. To evaluate HbA1c as a predictor for GDM 
and preeclampsia together with other data, we used logis-
tic regression with backwards elimination to find the best 
combination of variables in predicting the outcome. We 
used receiver operating characteristic (ROC) curve analy-
sis to evaluate the diagnostic accuracy of HbA1c alone, 
the models predicting GDM and to find suitable diagnos-
tic thresholds for not performing an OGTT [22]. We also 
assessed goodness-of-fit for the models by the Hosmer–
Lemeshow test. The leverage of individual points was visu-
ally judged by inspecting a plot of �βˆi against p, where �βˆi 
is the amount that the logistic regression model parame-
ters change when the ith observation is omitted from the 
model, and p is the estimated probability of the outcome.
To find the best combination of variables predicting birth 
weight, we used linear regression. Model assumptions and 
fit and identification of observations with potentially high 
influence on the model were evaluated by inspection of 
residual plots, R2 and the DFBETA statistic which quanti-
fies how much the regression coefficients change when the 
ith observation is omitted from the model.
For all regression analyses we used the Royston and 
Altman algorithm to find the simplest (if any) non-lin-
ear transformation of the continuous variables [23]. The 
selection of variables was based on variables that should 
be easily available to the clinician at the time point of 
HbA1c testing and known to be associated with or sus-
pected to influence on the dependent variable. Also, we 
included the intervention as a possible predictor vari-
able in all models for GDM at week 32–36 and through-
out pregnancy, preeclampsia and birth weight in order to 
adjust for possible confounding. The significance level for 
keeping a variable in the model was p value ≤0.10.
We used bootstrap analysis to assess the stability of the 
multivariable models where the bootstrap inclusion frac-
tion is an indicator for the importance of each independ-
ent variable [24].
The statistical analyses were performed using Stata ver-
sion 13.1 for Windows (Stata Corp., Texas, USA).
Results
In all, 855 women were included in the study. One hun-
dred twenty-eight were lost to follow-up, 25 did not 
complete the OGTT at pregnancy weeks 18–22, and 25 
did not complete an OGTT at pregnancy weeks 32–36. 
Due to missing data 627–677 women were included in 
the analyses (Fig.  1 and Table  1). Women with missing 
data were more often smokers (2.4 vs 0.5  %, p  =  0.02) 
and had slightly higher systolic blood pressure (median 
110 vs 108 mmHg, p = 0.03) and body mass index (BMI) 
(median 24.7 vs 24.2 kg/m2, p = 0.01). Table 1 lists char-
acteristics of the study population. The distribution of 
HbA1c at gestational week 32–36 among those diag-
nosed with and without GDM by the IADPSG criteria at 
gestational week 32–36 is shown in Fig. 2.
HbA1c as a screening test for GDM‑WHO
It was impossible to assess HbA1c as a screening test for 
GDM-WHO around 20  weeks of pregnancy, since only 
five (0.7  %) women tested positive for GDM-WHO at 
pregnancy weeks 18–22. Between the 32nd and the 36th 
weeks of gestation, 37 (5.8  %) women were diagnosed 
with GDM-WHO and throughout pregnancy (i.e. diag-
nosed at pregnancy weeks 18–22 or 32–36) 42 (6.7  %) 
women were diagnosed with GDM-WHO.
The area under the ROC curve for HbA1c in diagnos-
ing GDM-WHO at pregnancy weeks 32–36 was 0.74 
(95  % CI 0.64–0.83). HbA1c at 32–36  weeks of preg-
nancy, age and BMI at inclusion, family history of diabe-
tes mellitus (yes/no), GDM in previous pregnancy (yes/
no), previously giving birth to a macrosomic baby (yes/
no) and intervention (i.e. being in the exercise group or 
control group) were potential predictors for the model 
for GDM-WHO at pregnancy weeks 32–36. Only HbA1c 
and age were included in the model (Table  2), with an 
area under the ROC curve of 0.76 (95  % CI 0.66–0.85). 
Sensitivity and specificity for diagnosing GDM at various 
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levels of HbA1c and the predicted probability of GDM 
from the model are presented in Table 3.
For HbA1c at week 18–22 in diagnosing GDM-WHO 
throughout pregnancy, the area under the ROC curve 
was 0.64 (95 % CI 0.55–0.72). HbA1c at week 18–22, age, 
BMI, family history of diabetes mellitus, GDM in previ-
ous pregnancy, previously giving birth to a macrosomic 
baby and intervention were potential predictors for the 
model for GDM-WHO throughout pregnancy. Predic-
tors included in the model were HbA1c, age and a fam-
ily history of diabetes (Table 2). The area under the ROC 
curve for the model was 0.67 (95 % CI 0.58–0.76). Table 3 
presents sensitivity and specificity for diagnosing GDM 
at potential cut-offs for HbA1c and the predicted prob-
ability of GDM from the model.
None of those with GDM-WHO were diagnosed because 
of an elevated fasting s-glucose. With only 2-h s-glucose 
≥7.8  mmol/L as the outcome, fasting s-glucose had about 
the same diagnostic accuracy and ability to potentially reduce 
the number of OGTTs as HbA1c. Including fasting s-glucose 
in the models predicting a 2-h s-glucose ≥7.8 mmol/L did 
not improve the screening ability significantly.
HbA1c as a screening test for GDM‑IADPSG
At pregnancy weeks 18–22, 32–36 and throughout preg-
nancy (i.e. at week 18–22 or 32–36) 16 (2.4 %), 29 (4.6 %) 
and 45 (7.2  %) women were diagnosed with GDM-
IADPSG, respectively.
The area under the ROC curve for HbA1c in diagnos-
ing GDM-IADPSG at pregnancy weeks 18–22 was 0.67 
(95  % CI 0.54–0.80). HbA1c at 18–22  weeks of preg-
nancy, age, BMI, family history of diabetes mellitus, 
GDM in previous pregnancy and previously giving birth 
to a macrosomic baby were potential predictors for the 
model for GDM-IADPSG at pregnancy weeks 18–22. 
HbA1c and BMI were the only predictors included in 
the model (Table 2), with an area under the ROC curve 
of 0.70 (95 % CI 0.57–0.84). Potential cut-offs for HbA1c 
and the predicted probability of GDM with correspond-
ing sensitivity and specificity for diagnosing GDM are 
presented in Table 3.
HbA1c had an area under the ROC curve of 0.76 
(95  % CI 0.67–0.85) in diagnosing GDM-IADPSG at 
32–36  weeks of pregnancy. HbA1c at weeks 32–36, 
age, BMI, family history of diabetes mellitus, GDM in 
Fig. 1 Flow diagram of the study participants. The information in the lowest row shows how many of the study participants that had a complete 
data set for all potential predictors considered in the model, i.e. the number of participants included in the analyses for HbA1c alone and for HbA1c 
together with other data at that time point
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previous pregnancy, previously giving birth to a mac-
rosomic baby and intervention were potential predictors 
for the model for GDM-IADPSG at pregnancy weeks 
32–36. HbA1c, BMI and intervention were the predictors 
included in the model. We assessed possible interaction 
between HbA1c and intervention, but the interaction 
term was not statistically significant (p =  0.71), and we 
excluded the intervention variable from the model. The 
area under the ROC curve for the model with HbA1c and 
BMI as predictors (Table 2) was 0.77 (95 % CI 0.68–0.87). 
Table  3 shows sensitivity and specificity for diagnosing 
GDM at potential cut-offs for HbA1c and the predicted 
probability of GDM estimated by the model.
The area under the ROC curve for HbA1c at pregnancy 
weeks 18–22 in predicting GDM-IADPSG throughout 
pregnancy was 0.69 (0.60–0.77). HbA1c at 18–22 weeks 
of pregnancy, age, BMI, family history of diabetes melli-
tus, GDM in previous pregnancy, previously giving birth 
to a macrosomic baby and intervention were potential 
predictors for the model for GDM-IADPSG through-
out pregnancy. HbA1c and BMI were included in the 
model (Table  2) with an area under the ROC curve of 
0.72 (0.64–0.80). Sensitivity and specificity for diagnosing 
GDM at various levels of HbA1c and the predicted prob-
ability of GDM from the model are shown in Table 3.
Table 1 Characteristics of the study population
N Median (min–max) or n (%)
Age (years) 839 30 (19–46)
BMI (kg/m2) 854 24.3 (18.4–39.9)
Education at university college or 
university level
855 753 (88.1)
Exercised at moderate to high 
intensity at least three times per 
week prior to pregnancy
855 269 (31.5)
Nulliparity 853 485 (56.9)
Family history of diabetes 716 64 (8.9)
GDM in previous pregnancy 855 4 (0.4)
Previous macrosomic baby 855 70 (8.2)
Intervention group 855 429 (50)
Smoking in week 18–22 855 9 (1.1)
Systolic blood pressure week 18–22 
(mmHg)
855 109 (82–147)
HbA1c week 18–22 [%, (mmol/mol)] 845 4.8 (4.2–5.7) [29 (22–39)]
HbA1c week 32–36 [%, (mmol/mol)] 722 5.1 (4.4–5.8) [32 (25–40)]
Fasting s-glucose week 18–22 
(mmol/L)
849 4.3 (3.4–5.6)
2-h s-glucose week 18–22 (mmol/L) 836 4.8 (2.1–10.1)
Fasting s-glucose week 32–36 
(mmol/L)
711 4.3 (3.2–6.4)
2-h s-glucose week 32–36 (mmol/L) 702 5.6 (2.3–9.9)
Birth weight (g) 853 3540 (825–4930)
Fig. 2 The distribution of HbA1c at pregnancy weeks 32–36 in those diagnosed with gestational diabetes mellitus (black columns) and not (grey 
columns) at gestational week 32–36 by the modified IADPSG criteria. In addition to the histograms, the figure shows a kernel density plot of HbA1c 
in each group, where the distributions are smoothed and scaled to the same level of probability density
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Only four women had history of GDM in a previous 
pregnancy and none of them had GDM-IADPSG, so 
this variable was omitted from the analyses of GDM-
IADPSG. We performed the analyses for the multivari-
able models for GDM-IADPSG without the previous 
GDM variable, and a sensitivity analyses without those 
with previous GDM. The results did not change after 
exclusion of those with previous GDM.
HbA1c as predictor for preeclampsia
The prevalence of preeclampsia was 2.9 %. Predictor vari-
ables considered for the preeclampsia model were HbA1c 
at 18–22  weeks of pregnancy, age, BMI, smoking (yes/
no) and systolic blood pressure at inclusion, interven-
tion, nulliparity and GDM-WHO. We also performed the 
analyses with GDM-IADPSG as an independent variable 
instead of GDM-WHO, and with HbA1c at weeks 32–36 
instead of at weeks 18–22. Variables included in the 
model for preeclampsia were GDM-WHO (OR 2.97, 95 % 
CI 0.82–10.7, p = 0.10) and nulliparity (OR 2.80, 95 % CI 
0.92–8.5, p =  0.07). The area under the ROC curve for 
this model was 0.67 (95 % CI 0.58–0.76). Neither HbA1c 
at pregnancy weeks 18–22 or 32–36 nor GDM-IADPSG 
were statistically significantly associated with preeclamp-
sia (p > 0.10).
None of the nine women who smoked had preeclamp-
sia, and this variable was omitted from the analyses of 
the model for preeclampsia. We therefore performed the 
analyses without the smoking variable, and a sensitiv-
ity analyses without those smoking. The results did not 
change after exclusion of those who smoked.
HbA1c as predictor for birth weight
The following predictor variables were considered for 
the model predicting birth weight; HbA1c at pregnancy 
weeks 18–22, age, BMI and smoking at inclusion, inter-
vention, nulliparity, previously giving birth to a mac-
rosomic baby and GDM-WHO. We also performed the 
analyses with GDM-IADPSG as an independent vari-
able instead of GDM-WHO, and with HbA1c at preg-
nancy weeks 32–36 instead of at weeks 18–22. Variables 
included in the model for birth weight were HbA1c 
at pregnancy weeks 32–36 (β 137, 95 % CI −10 to 283, 
p = 0.07), BMI (β 35, 95 % CI 23–47, p < 0.0005), nulli-
parity (β −102, 95 % CI −178 to −28, p = 0.008) and pre-
viously giving birth to a macrosomic baby (β 301, 95 % CI 
161–440, p < 0.0005). Neither HbA1c at pregnancy weeks 
18–22, GDM-WHO nor GDM-IADPSG were statistically 
significantly associated with birth weight (p > 0.10).
We did not find any non-linear associations between 
the continuous variables and the outcome for any of the 
models. We assessed the stability of the multivariable 
models by bootstrap analysis [24]. The results were in 
consistence with our final models as HbA1c was selected 
in 74–100 % of the replicates for all GDM models, except 
for the model predicting GDM-IADPSG at pregnancy 
weeks 18–22 where it was chosen in 31  % of the repli-
cates. For the other predictors of GDM, only BMI in the 
model for GDM-IADPSG throughout pregnancy was 
chosen in more than 60 % of the replicates (79 %).
Discussion
Around 30 % of pregnant women could potentially have 
avoided an OGTT by using HbA1c ≤4.8  % (29  mmol/
mol) to exclude GDM-IADPSG with a sensitivity of 88 % 
at pregnancy weeks 18–22 and by using HbA1c ≤5.0 % 
(31  mmol/mol) with a sensitivity of 97  % at pregnancy 
weeks 32–36 (Table  3). Further, 16  % could potentially 
have avoided an OGTT with a sensitivity of 96  % by 
using HbA1c ≤4.7 % (28 mmol/mol) at pregnancy weeks 
18–22 to exclude GDM-IADPSG throughout pregnancy 
(Table 3). Adding other variables to predict GDM did not 
significantly increase the number of potentially avoidable 
OGTTs. HbA1c was not accurate at diagnosing GDM-
IADPSG since most of those diagnosed would have been 
false positives (Table 3). HbA1c was inaccurate at screen-
ing for GDM-WHO at any time point. Neither HbA1c 
nor GDM was accurate in predicting preeclampsia or 
birth weight.
Agarwal et  al. studied HbA1c as a screening test for 
GDM by WHO 1999 criteria in gestational weeks 24–28 
[8]. They found an area under the ROC curve of 0.54 
(95  % CI 0.48–0.61), significantly lower than our result 
at pregnancy weeks 32–36, but similar to our result for 
HbA1c from pregnancy weeks 18–22 in diagnosing 
GDM-WHO throughout pregnancy. They also found 
that when high levels of HbA1c were used to diagnose 
GDM, most positive test results would be false positives. 
At thresholds they considered had acceptable sensitiv-
ity, they could only exclude GDM in a few women. They 
also concluded that HbA1c is unsuitable for screening for 
GDM-WHO.
Rajput et al. and Sevket et al. found an area under the 
ROC curve for HbA1c in diagnosing GDM by IADPSG 
criteria in pregnancy weeks 24–28 of 0.683 (95  % CI 
0.601–0.765) when screening 607 Indian women and 
0.697 (95 % CI 0.645–0.745) among 339 women in Tur-
key, respectively [10, 12], both were comparable to our 
results. Although the overall diagnostic accuracy for 
HbA1c in diagnosing GDM by IADPSG criteria was sim-
ilar for the present and previous studies, the diagnostic 
thresholds for HbA1c and the sensitivity and specificity 
at the same levels of HbA1c differ between studies [10, 
12]. These differences probably reflect diversities between 
populations, testing at different gestational lengths and 
the analytical methods used. However, there are also 
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similarities in the studies: HbA1c is not accurate at diag-
nosing GDM; around 45  % of those ruled-into GDM 
would have been false positives in the study of Rajput 
et al. [10], 67 % in the study of Sevket et al. [12] and more 
than 60 % in our study (Table 3). Using HbA1c to exclude 
GDM, 35 % could have potentially avoided OGTT in the 
study by Rajput et  al. with a false negative rate of 17  % 
[10], and 21 % in the study by Sevket and colleagues with 
a false negative rate of 4 % [12]. In our study around 30 % 
could have avoided an OGTT with a false negative rate 
of 3  % (i.e. sensitivity 97  %) at pregnancy weeks 32–36 
(Table 3).
The strengths of our study are the inclusion of other 
clinical variables in the multivariable prediction mod-
els and the possibility to evaluate prediction of GDM by 
both WHO and modified IADPSG diagnostic criteria.
Our study has limitations. The number of women 
with GDM was low, and this increases the risk of a type 
II error. The study participants were healthy, highly-
educated, Caucasian women with low-risk pregnancies 
(Table  1). Our results may not be relevant in popula-
tions with higher BMI, less physical activity and educa-
tion or other ethnicities. Furthermore, only 73–79  % of 
those originally included in the randomized controlled 
trial were included in the present analyses. Women lost 
to follow-up could have led to a further selection of low-
risk pregnancies. The differences in smoking rate (2.4 vs 
0.5 %, p = 0.02), systolic blood pressure (median 110 vs 
108 mmHg, p = 0.03) and BMI (median 24.7 vs 24.2 kg/
m2, p  =  0.01) for those with missing data versus those 
with complete data could suggest that, however, the 
absolute differences were small and the clinical signifi-
cance questionable. It is most common to test for GDM 
around gestational week 24–28, so our timing of testing 
is a weakness of the study.
Like some previous studies [25, 26] we used modified 
IADPSG criteria, since 1-h s-glucose was not available in 
our study. Thus, we cannot exclude misclassification of 
some women as normal glucose tolerant instead of GDM. 
Studies indicate that 14–21  % of GDM cases according 
to IADPSG criteria are diagnosed by the 1-h value alone 
[27–29]. Accordingly, up to one-fifth of GDM-IADPSG 
cases may be misclassified as non-GDM-IADPSG. Most 
probably these women had HbA1c in the upper range. In 
sensitivity analyses we found that even if 20 % were mis-
classified and all of them had high HbA1c values, reclas-
sifying them as GDM would not change the figures in 
Table 3 significantly.
OGTT may be questioned as gold standard. In some 
studies, 22–24  % of pregnant women were reclassified 
when the OGTT was measured 1–2  weeks apart [30, 
31]. Furthermore, the WHO 1999 criteria are based on 
risk for diabetes-specific microvascular complications in 
non-pregnant populations, and the IADPSG criteria are 
based on an increased risk for birth weight, cord C-pep-
tide and percentage body fat above the 90th percentile 
[32]. Thus, GDM is more a risk factor than a disease per 
se. GDM carries a rather small increased risk for preg-
nancy complications and adverse pregnancy outcomes, 
and most women diagnosed do not develop complica-
tions [33]. In one study, the area under the ROC curve 
for IADPSG criteria in predicting a composite adverse 
pregnancy outcome including preeclampsia, large-for-
gestational age newborn and perinatal death, was 0.582 
(95 % CI 0.559–0.604) [34].
Although HbA1c is not very good at diagnosing GDM, 
it may have a potential to predict adverse pregnancy 
outcomes. We found that HbA1c was unable to predict 
preeclampsia. However, we had few women with preec-
lampsia (n = 19, 2.9 %) and low power to detect a pos-
sible association. Others have found an association 
between HbA1c and preeclampsia [35, 36].
In the model predicting birth weight, HbA1c at preg-
nancy weeks 32–36 was included (β 137, 95  % CI −10 
to 283, p  =  0.07). However, the association was only 
borderline statistically significant, and in an evaluation 
of the stability of the model [24], it was only selected in 
23 % of the replicates. The HAPO study found that asso-
ciations with birth weight were significantly stronger for 
glucose than for HbA1c [35]. Hou et al. found no signifi-
cant difference in HbA1c at pregnancy weeks 28–37 in 
non-diabetic women having newborns appropriate-for-
gestational age compared to large-for-gestational age 
[37]. In contrast, Karcaaltincaba and co-workers found 
a positive and independent association between second 
trimester HbA1c and birth weight and none between 
fasting plasma glucose and birth weight in non-dia-
betic pregnancies [38]. Hughes et  al. found that a high 
HbA1c before pregnancy week 20 was associated with an 
increased risk of large-for-gestational age newborn, but 
not macrosomia [36]. However, a high HbA1c was asso-
ciated with an increased risk of major congenital anom-
aly, preeclampsia, shoulder dystocia, and perinatal death 
[36].
Those diagnosed with GDM-WHO in the present study 
received standard treatment for GDM, i.e. diet and life 
style advice, and could thereby have prevented adverse 
outcomes. This may be an explanation for no or weak 
associations between the predictor variables and the 
adverse pregnancy outcomes.
Conclusions
HbA1c may have a potential for screening for GDM since 
it is possible to exclude GDM in a significant propor-
tion of women. Whether HbA1c alone or combined with 
other data can be useful in predicting adverse pregnancy 
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outcomes among normal healthy women is unclear, and 
more research is needed.
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